Last reviewed 2026-05-13 · How we verify

TAK-536 Dry Syrup Formulation

Takeda · Phase 1 active Small molecule

TAK-536 Dry Syrup Formulation is a Small molecule drug developed by Takeda. It is currently in Phase 1 development.

At a glance

Generic name	TAK-536 Dry Syrup Formulation
Sponsor	Takeda
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Bioequivalence Study of TAK-536 Pediatric Formulation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TAK-536 Dry Syrup Formulation CI brief — competitive landscape report
TAK-536 Dry Syrup Formulation updates RSS · CI watch RSS
Takeda portfolio CI

Frequently asked questions about TAK-536 Dry Syrup Formulation

What is TAK-536 Dry Syrup Formulation?

TAK-536 Dry Syrup Formulation is a Small molecule drug developed by Takeda.

Who makes TAK-536 Dry Syrup Formulation?

TAK-536 Dry Syrup Formulation is developed by Takeda (see full Takeda pipeline at /company/takeda).

What development phase is TAK-536 Dry Syrup Formulation in?

TAK-536 Dry Syrup Formulation is in Phase 1.

Manufacturer: Takeda — full pipeline
Compare: TAK-536 Dry Syrup Formulation vs similar drugs
Pricing: TAK-536 Dry Syrup Formulation cost, discount & access